A comparative study of current Medicaid prescription reimbursement (MAC/EAC) (maximum allowable cost/estimated acquisition cost) with prescription reimbursement based on a competitive market. - Suppr | 超能文献

A comparative study of current Medicaid prescription reimbursement (MAC/EAC) (maximum allowable cost/estimated acquisition cost) with prescription reimbursement based on a competitive market.

作者信息

Porter B H, Carroll N V, Kotzan J A

出版信息

J Pharm Mark Manage. 1988;3(2):37-46. doi: 10.3109/j058v03n02_04.

DOI:10.3109/j058v03n02_04

Abstract

Many pharmacists have suggested that the current Maximum Allowable Cost/Estimated Acquisition Cost (MAC/EAC) program has departed from its intended purpose of generating savings by taking full but fair advantage of the competitive marketplace. The objective of this study was to compare Medicaid prescription reimbursement under current MAC/EAC regulations with prescription reimbursement based on a competitive market. Data representing the top selling single source and multiple source drug products for nine states were analyzed. Results indicated that the current MAC/EAC system of Medicaid reimbursement produced a small savings when compared to reimbursement based on a competitive market.

摘要

相似文献

1

A comparative study of current Medicaid prescription reimbursement (MAC/EAC) (maximum allowable cost/estimated acquisition cost) with prescription reimbursement based on a competitive market.

J Pharm Mark Manage. 1988;3(2):37-46. doi: 10.3109/j058v03n02_04.

2

Evaluation of the maximum allowable cost program.

Health Care Financ Rev. 1983 Mar;4(3):71-82.

3

MAC regulations: their predicted economic impact on pharmaceutical reimbursement.

Contemp Pharm Pract. 1981 Winter;4(1):32-6.

4

Assessing potential prescription reimbursement changes: estimated acquisition costs in Wisconsin.

Health Care Financ Rev. 1989 Spring;10(3):67-75.

5

Third-party reimbursement for generic prescription drugs: The prevalence of below-cost reimbursement in an environment of maximum allowable cost-based reimbursement.

J Am Pharm Assoc (2003). 2018 Jul-Aug;58(4):421-425. doi: 10.1016/j.japh.2018.04.018. Epub 2018 May 31.

6

Pharmaceutical Reimbursement Board; suspension of maximum allowable cost limits on specific drug products--HCFA.

Fed Regist. 1983 Sep 30;48(191):44931.

7

Pharmaceutical Reimbursement Board; final maximum allowable cost (MAC) determinations for certain drug products--Health Care Financing Administration. Final notice.

Fed Regist. 1982 Dec 30;47(251):58370-2.

8

Pharmaceutical reimbursement and drug cost control: the MAC experience in Maryland.

Inquiry. 1983 Spring;20(1):76-87.

9

Pharmaceutical Reimbursement Board; rinal maximum allowable cost (MAC) determinations for certain drug products--HCFA. Final notice for maximum allowable cost determinations.

Fed Regist. 1982 Jun 28;47(124):27968-73.

10

Differences in the cost of antidepressants across state Medicaid programs.

J Ment Health Policy Econ. 2008 Mar;11(1):33-47.

引用本文的文献

1

Economic impact of cost-containment strategies in third party programmes in the US (part I).

Pharmacoeconomics. 1993 Aug;4(2):92-103. doi: 10.2165/00019053-199304020-00004.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。